Skip to main content

1-20 of 54 results for subject:CJD

Primary member X
Hinchliffe, David

Type

House

Session

Year

Department

Member

More

Primary member

Hinchliffe, David (54)
More

Answering member

Legislative stage

Legislation

Subject

More

Publisher


Show detailed: On Off
Results: 10 20 50 100
Sort by: Newest first Oldest first

To ask the Secretary of State for Health, if the SEAC has been asked for its opinion as to the potential efficacy of pentosan polysulphate in treating nvCJD; and if he will make a statement; what is the cost of an oral course of pentosan polysulphate as prophylaxis against nvCJD....

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
10 February 1999
Reference
325 c219W; 61679;61680
House
House of Commons

To ask the Secretary of State for Health, what action his Department is taking to discover methods of treatment for people who may be infected with new-variant CJD; and what reports he has received regarding chemicals which can prevent the transmission of spongiform encephalopathies, with particular reference to (a) potentially...

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
9 July 1998
Reference
315 c612W; 49658;49657
House
House of Commons

To ask the Secretary of State for Health, if he will publish his Department's latest figures for trends in suspected and confirmed cases of Creutzfeldt Jakob Disease in the United Kingdom. - Inc ref to press release on 6 October 1997 (in Library).

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
27 October 1997
Reference
12492; 299 c761W
House
House of Commons

To ask the Secretary of State for Health, how many cases of Creutzfeldt Jakob Disease in the United Kingdom resulted from contaminated implements during surgical procedures.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
27 October 1997
Reference
12493; 299 c761W
House
House of Commons

What estimate she has made of the legal costs incurred to date by the Treasury Solicitor on behalf of the Medical Research Council in respect of CJD litigation.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Trade and Industry
Type
Written questions
Status
Answered
Date
1 July 1997
Reference
6083; 297 c97-8W
House
House of Commons

What estimate he has made of the legal costs to date incurred by his Department and the Treasury Solicitor acting on behalf of the Medical Research Council, indicating separately disbursements and counsel fees, of the defence from claims brought against his Department and the Medical Research Council in respect of...

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
25 June 1997
Reference
5111; 296 c539W;296 c541W
House
House of Commons

What financial provision has been made for the costs of caring for those affected by new variant CJD; over what period these costs are expected to be incurred.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
10 March 1997
Reference
18254; 292 c108W
House
House of Commons

What tests are available to demonstrate that blood does not contain the agent of new variant CJD.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
3 March 1997
Reference
18022; 291 c517W
House
House of Commons

Adjournment debate on Creutzfeldt-Jakob disease and human growth hormone treatment.

Lead member
David Hinchliffe
Answering member
Lord Horam
Department
Department of Health
Type
Adjournment debates
Date
24 February 1997
Reference
291 c123-30
House
House of Commons

What steps have been taken to evaluate the possible causes of the cluster of CJD and suspected CJD cases in Kent.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
12 February 1997
Reference
15259; 290 c182W
House
House of Commons

If he will publish his plans for research concerning BSE.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
6 November 1996
Reference
188; 284 c569W
House
House of Commons

What potential methods of treatment are being (a) planned and (b) evaluated in respect of human equivalents to BSE.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
6 November 1996
Reference
189; 284 c569-70W
House
House of Commons

If he will comment on the implications for his policy on BSE/CJD of the latest medical findings of Professor John Collinge.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
29 October 1996
Reference
841; 284 c93W;284 c94W
House
House of Commons

If he will establish an independent judicial inquiry into BSE and CJD.

Asked by
David Hinchliffe (Labour)
Answering body
Prime Minister
Type
Written questions
Status
Answered
Date
29 October 1996
Reference
842; 284 c72W
House
House of Commons

That this House, whilst welcoming the recent decision of Mr Justice Morland in the Creutzfeldt-Jakob Disease litigation, nevertheless notes with concern that it was necessary for this forensic judicial inquiry to take place because of the failure of the Secretary of State for Health to order a public inquiry akin...

Primary sponsor
David Hinchliffe (Labour)
Type
Early day motions
Date
22 July 1996
Reference
1203
House
House of Commons

What is the range of ages of the current 20 cases of the new strain of Creutzfeldt Jakob's Disease referred to by Dr James Ironside of the Creutzfeldt Jakob's Disease surveillance unit, Edinburgh, on 14th June.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
25 June 1996
Reference
33835; 280 c86W
House
House of Commons

When he was first advised of a possible new strain of Creutzfeldt-Jakob Disease; and if he was informed of any change in the assessment of health risks associated with BSE in cattle, arising out of this discovery.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
1 April 1996
Reference
23171; 275 c45W
House
House of Commons

How many confirmed cases of Creutzfeldt Jakob disease have been notified for people aged (a) under 20 years, (b) 20 to 30 years, (c) 31 to 40 years, (d) 41 to 50 years, (e) 51 to 60 years and (f) 60 years and over; and how many were (i) male...

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
1 April 1996
Reference
23218; 275 c46W
House
House of Commons

How much money his Department spent on research into CJD in each of the last five financial years. - Includes figures.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
1 April 1996
Reference
24023; 275 c46W
House
House of Commons

Which organisations will receive funding for the proposed additional research into CJD; and if future CJD research funded out of NHS research budget will include transmission studies. - Includes ref to 274 c710-2.

Asked by
David Hinchliffe (Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Date
1 April 1996
Reference
275 c46W; 24021;24022
House
House of Commons